Mulberry -Alexion 1850-305

Learn More

Other Studies:

CARAT – EFC 16158

Recruiting, Fabry Disease

CARAT - EFC 16158Summary: This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate...

Hickory -Alexion 1850-301

Hypophosphatasia, Recruiting

Hickory - Alexion 1850-301

Eli Kids EFC13738

Active: Not Recruiting, Gaucher Disease

Eli Kids EFC13738 Summary: Evaluate the safety and pharmacokinetics of eliglustat in pediatric patients

Contact Us



+1 (587) 885-3158



+1 (587) 441-8380



clinic@magiccalgary.ca



215 – 971 64 Ave NE, Calgary, Alberta, Canada, T2E 7Z4